Hormone blockers are medications that either stop the body from producing certain hormones or prevent those hormones from doing their job. They work in different ways depending on the type, but the core idea is the same: reduce the influence of a specific hormone on the body. Doctors prescribe them for a wide range of conditions, from breast and prostate cancer to endometriosis, polycystic ovary syndrome (PCOS), and gender-affirming care for transgender adolescents.
How Hormone Blockers Work
Your body’s hormone system runs on a chain of signals. The brain sends chemical messages to glands, which then release hormones like estrogen and testosterone into the bloodstream. Hormone blockers can interrupt this chain at different points.
The most well-known type targets a signal called gonadotropin-releasing hormone (GnRH), which the brain sends to the pituitary gland to trigger sex hormone production. GnRH agonists mimic this signal so persistently that the pituitary gland essentially burns out its receptors and stops responding, shutting down hormone production over a period of weeks. GnRH antagonists take a more direct route: they physically block the receptor, suppressing hormone production within hours.
Other hormone blockers work further downstream. Some block the receptors on cells so that hormones circulating in the blood can’t attach and activate them. Others shut down specific enzymes the body needs to manufacture hormones in the first place. The type a doctor chooses depends entirely on the condition being treated and which hormone needs to be controlled.
Hormone Blockers in Cancer Treatment
Many breast and prostate cancers rely on sex hormones to grow. Cutting off that fuel supply is one of the most effective strategies for slowing or stopping these cancers.
Breast Cancer
In hormone receptor-positive breast cancer, the tumor has receptors that respond to estrogen. One widely used medication works by binding to those receptors first, blocking estrogen from reaching the cancer cells. For premenopausal patients, this is typically the first-line option and may be combined with ovarian suppression in more advanced cases. Postmenopausal patients have additional options, including medications that block the enzyme responsible for converting other hormones into estrogen, effectively lowering estrogen levels throughout the body. These treatments are often prescribed as adjuvant therapy, meaning they’re taken after surgery to reduce the chance of the cancer returning, sometimes for five years or longer.
Prostate Cancer
Prostate cancer is driven by testosterone. Androgen deprivation therapy uses GnRH agonists or antagonists to suppress testosterone to extremely low levels. Historically, the target was below 50 ng/dL, but experts now agree that pushing below 20 ng/dL leads to better survival and slower disease progression. For context, normal testosterone in adult men typically ranges from 300 to 1,000 ng/dL, so these medications reduce it dramatically.
Puberty Suppression in Transgender Youth
GnRH agonists are used in gender-affirming care to pause puberty in transgender and gender diverse adolescents. By blocking the pituitary gland’s response, these medications prevent the development of secondary sexual characteristics like breast growth, voice deepening, and facial hair. This gives young people and their families more time to make decisions about further care without the distress of going through a puberty that conflicts with their gender identity.
International clinical guidelines recommend starting puberty suppression only after puberty has already begun, specifically at Tanner stage 2. For those assigned female at birth, this means breast budding has started. For those assigned male at birth, it means testicular growth has reached a certain threshold. There is no specific age cutoff in the guidelines; the milestone is physical, not chronological. The reasoning is that experiencing the very earliest signs of puberty may be an important part of the adolescent’s own understanding of their gender identity.
Most effects of puberty suppression are reversible. If the medication is stopped, the body resumes sex hormone production and puberty picks back up. However, long-term use does affect bone development, which is an important consideration.
Other Conditions Treated With Hormone Blockers
Hormone blockers have applications well beyond cancer and gender-affirming care. In endometriosis, GnRH agonists suppress estrogen to reduce the growth of tissue outside the uterus, easing pain for many patients. For PCOS, medications that block the effects of androgens (sometimes called “male hormones,” though all bodies produce them) can help manage symptoms like excess hair growth. Doses for androgen-blocking treatment in PCOS typically range from 100 to 200 mg daily, and these are usually combined with a form of hormonal birth control.
Children who enter puberty abnormally early, a condition called central precocious puberty, are also treated with GnRH agonists. In this case, the goal is to pause premature development and allow the child to reach a more typical age before puberty resumes.
Side Effects and What to Expect
Because hormone blockers reduce hormones that affect nearly every system in the body, side effects are common and vary by type. Hot flashes are one of the most frequent complaints across almost all categories of hormone-blocking therapy. Joint pain, fatigue, mood changes, and sleep disturbances are also widely reported, particularly among breast cancer patients on long-term adjuvant therapy.
Managing these side effects can be frustrating. For fatigue, yoga and aerobic exercise have the strongest evidence behind them. For vaginal dryness, moisturizers and lubricants are consistently recommended. But for hot flashes, the evidence for self-management strategies like supplements, acupuncture, or relaxation techniques is generally weak or inconsistent. Taking certain medications with food or at bedtime can help with nausea, though this is based more on clinical experience than rigorous studies.
Effects on Bone Health
One of the most significant concerns with hormone blockers, particularly in younger patients, is their impact on bones. Sex hormones play a critical role in building bone density, especially during adolescence when the body is laying down the bone mass it will carry into adulthood.
Studies on transgender youth show that puberty suppression lasting roughly one to two years leads to measurable declines in bone density at the spine and hip. When sex hormones are later introduced (either estrogen or testosterone as part of gender-affirming hormone therapy), bone density does trend upward over the following two to three years. But in many cases, it doesn’t fully return to the levels measured before treatment began. This is an area doctors monitor closely, and it factors into decisions about how long to continue puberty suppression before moving to the next stage of care.
In adults being treated for cancer, the same principle applies. Long-term suppression of estrogen or testosterone accelerates bone thinning, increasing fracture risk. Weight-bearing exercise and sometimes additional medications to protect bones become part of the overall treatment plan.
How Long Treatment Lasts
Duration depends entirely on the reason for treatment. Breast cancer patients on adjuvant hormone-blocking therapy often take it for five years, sometimes longer. Prostate cancer patients may remain on androgen deprivation therapy indefinitely if their cancer is advanced. For transgender adolescents, puberty suppression is generally a bridge until they and their care team decide on the next step, whether that’s starting gender-affirming hormones or, less commonly, discontinuing treatment and allowing natal puberty to resume. For endometriosis or precocious puberty, treatment courses tend to be shorter and are guided by symptom control and developmental milestones.